PACS Group (NYSE:PACS) vs. Aclarion (NASDAQ:ACON) Head-To-Head Review

Aclarion (NASDAQ:ACON) and PACS Group (NYSE:PACS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Aclarion and PACS Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	37.03	-$7.23 million	($17.01)	-0.20
PACS Group	$5.29 billion	1.00	$191.54 million	$1.23	27.41

PACS Group has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Aclarion has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, PACS Group has a beta of -0.64, suggesting that its share price is 164% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Aclarion and PACS Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	0	0	1.00
PACS Group	0	1	4	1	3.00

PACS Group has a consensus target price of $44.40, suggesting a potential upside of 31.70%. Given PACS Group’s stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than Aclarion.

Profitability

This table compares Aclarion and PACS Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-9,517.11%	-52.31%	-49.79%
PACS Group	3.62%	22.55%	3.45%

Institutional & Insider Ownership

7.5% of Aclarion shares are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 70.4% of PACS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

PACS Group beats Aclarion on 12 of the 15 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.